Surgical Treatment for Recurrent Bulbar Urethral Stricture: A Randomised Open-label Superiority Trial of Open Urethroplasty Versus Endoscopic Urethrotomy (the OPEN Trial).


Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
10 2020
Historique:
received: 23 09 2019
accepted: 02 06 2020
pubmed: 9 7 2020
medline: 16 7 2021
entrez: 9 7 2020
Statut: ppublish

Résumé

Urethral stricture affects 0.9% of men. Initial treatment is urethrotomy. Approximately, half of the strictures recur within 4 yr. Options for further treatment are repeat urethrotomy or open urethroplasty. To compare the effectiveness and cost-effectiveness of urethrotomy with open urethroplasty in adult men with recurrent bulbar urethral stricture. This was an open label, two-arm, patient-randomised controlled trial. UK National Health Service hospitals were recruited and 222 men were randomised to receive urethroplasty or urethrotomy. Urethrotomy is a minimally invasive technique whereby the narrowed area is progressively widened by cutting the scar tissue with a steel blade mounted on a urethroscope. Urethroplasty is a more invasive surgery to reconstruct the narrowed area. The primary outcome was the profile over 24 mo of a patient-reported outcome measure, the voiding symptom score. The main clinical outcome was time until reintervention. The primary analysis included 69 (63%) and 90 (81%) of those allocated to urethroplasty and urethrotomy, respectively. The mean difference between the urethroplasty and urethrotomy groups was -0.36 (95% confidence interval [CI] -1.74 to 1.02). Fifteen men allocated to urethroplasty needed a reintervention compared with 29 allocated to urethrotomy (hazard ratio [95% CI] 0.52 [0.31-0.89]). In men with recurrent bulbar urethral stricture, both urethroplasty and urethrotomy improved voiding symptoms. The benefit lasted longer for urethroplasty. There was uncertainty about the best treatment for men with recurrent bulbar urethral stricture. We randomised men to receive one of the following two treatment options: urethrotomy and urethroplasty. At the end of the study, both treatments resulted in similar and better symptom scores. However, the urethroplasty group had fewer reinterventions.

Sections du résumé

BACKGROUND
Urethral stricture affects 0.9% of men. Initial treatment is urethrotomy. Approximately, half of the strictures recur within 4 yr. Options for further treatment are repeat urethrotomy or open urethroplasty.
OBJECTIVE
To compare the effectiveness and cost-effectiveness of urethrotomy with open urethroplasty in adult men with recurrent bulbar urethral stricture.
DESIGN, SETTING, AND PARTICIPANTS
This was an open label, two-arm, patient-randomised controlled trial. UK National Health Service hospitals were recruited and 222 men were randomised to receive urethroplasty or urethrotomy.
INTERVENTION
Urethrotomy is a minimally invasive technique whereby the narrowed area is progressively widened by cutting the scar tissue with a steel blade mounted on a urethroscope. Urethroplasty is a more invasive surgery to reconstruct the narrowed area.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
The primary outcome was the profile over 24 mo of a patient-reported outcome measure, the voiding symptom score. The main clinical outcome was time until reintervention.
RESULTS AND LIMITATIONS
The primary analysis included 69 (63%) and 90 (81%) of those allocated to urethroplasty and urethrotomy, respectively. The mean difference between the urethroplasty and urethrotomy groups was -0.36 (95% confidence interval [CI] -1.74 to 1.02). Fifteen men allocated to urethroplasty needed a reintervention compared with 29 allocated to urethrotomy (hazard ratio [95% CI] 0.52 [0.31-0.89]).
CONCLUSIONS
In men with recurrent bulbar urethral stricture, both urethroplasty and urethrotomy improved voiding symptoms. The benefit lasted longer for urethroplasty.
PATIENT SUMMARY
There was uncertainty about the best treatment for men with recurrent bulbar urethral stricture. We randomised men to receive one of the following two treatment options: urethrotomy and urethroplasty. At the end of the study, both treatments resulted in similar and better symptom scores. However, the urethroplasty group had fewer reinterventions.

Identifiants

pubmed: 32636099
pii: S0302-2838(20)30430-9
doi: 10.1016/j.eururo.2020.06.003
pii:
doi:

Banques de données

ISRCTN
['ISRCTN98009168']

Types de publication

Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

572-580

Subventions

Organisme : Chief Scientist Office
ID : HSRU1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K02325X/1
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Auteurs

Beatriz Goulao (B)

Health Services Research Unit, University of Aberdeen, Aberdeen, UK.

Sonya Carnell (S)

Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK.

Jing Shen (J)

Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.

Graeme MacLennan (G)

Centre for Healthcare and Randomised Trials, University of Aberdeen, Aberdeen, UK.

John Norrie (J)

Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.

Jonathan Cook (J)

Centre for Statistics in Medicine, University of Oxford, Oxford, UK.

Elaine McColl (E)

Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.

Matt Breckons (M)

Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.

Luke Vale (L)

Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK. Electronic address: luke.vale@ncl.ac.uk.

Paul Whybrow (P)

Hull York Medical School, University of Hull, Hull, UK.

Tim Rapley (T)

Social Work, Education and Community Wellbeing, University of Northumbria, Newcastle upon Tyne, UK.

Rebecca Forbes (R)

Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK.

Stephanie Currer (S)

Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK.

Mark Forrest (M)

Centre for Healthcare and Randomised Trials, University of Aberdeen, Aberdeen, UK.

Jennifer Wilkinson (J)

Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK.

Daniela Andrich (D)

University College London Hospital, London, UK.

Stewart Barclay (S)

Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Anthony Mundy (A)

University College London Hospital, London, UK.

James N'Dow (J)

Academic Urology Unit, University of Aberdeen, Aberdeen, UK.

Stephen Payne (S)

Central Manchester Hospitals NHS Foundation Trust, Manchester, UK.

Nick Watkin (N)

St George's University Hospitals NHS Foundation Trust, London, UK.

Robert Pickard (R)

Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH